Bothe, Ulrich

[["dc.bibliographiccitation.firstpage","1296"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Chemistry - A European Journal"],["dc.bibliographiccitation.lastpage","1302"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Tietze, Lutz Friedjan"],["dc.contributor.author","Griesbach, U."],["dc.contributor.author","Schuberth, I."],["dc.contributor.author","Bothe, U."],["dc.contributor.author","Marra, A."],["dc.contributor.author","Dondoni, A."],["dc.date.accessioned","2018-11-07T10:39:58Z"],["dc.date.available","2018-11-07T10:39:58Z"],["dc.date.issued","2003"],["dc.description.abstract","The synthesis of the novel unprotected carboranyl C-glycosides 2 and 20 24 starting from ethynyl C-glycosides 1, 5-8, 10, and 13 is described. The new compounds are highly water-soluble and display only a very low cytotoxicity, which makes them promising candidates for use in boron neutron capture therapy for the treatment of cancer."],["dc.identifier.doi","10.1002/chem.200390148"],["dc.identifier.isi","000181817400005"],["dc.identifier.pmid","12645018"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46188"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-v C H Verlag Gmbh"],["dc.relation.issn","0947-6539"],["dc.title","Novel carboranyl C-glycosides for the treatment of cancer by boron neutron capture therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1747"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Bioorganic & Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","1752"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Tietze, Lutz Friedjan"],["dc.contributor.author","Bothe, U."],["dc.contributor.author","Griesbach, U."],["dc.contributor.author","Nakaichi, M."],["dc.contributor.author","Hasegawa, T."],["dc.contributor.author","Nakamura, H."],["dc.contributor.author","Yamamoto, Y."],["dc.date.accessioned","2018-11-07T08:53:51Z"],["dc.date.available","2018-11-07T08:53:51Z"],["dc.date.issued","2001"],["dc.description.abstract","Distinct biological properties of the ortho-carboranyl (1,2-dicarba-closo-dodecaboranyl) glycosides 1, 2 and 3 were evaluated to estimate the suitability of these compounds for cancer treatment by boron neutron capture therapy. The boron uptake into B16-Melanoma cells was significantly higher by incubating the cells with aqueous solutions of carboranyl glucoside 1 (11.2 ppm after 3 h), lactoside 2 (13.2 ppm after 12 h) and maltoside 3 (20.0 ppm after 24 h) compared with solutions of clinically used p-boronophenylalanine (BPA) 5 (3.1 ppm after 34 h), Carboranyl maltoside 3 was more effective than boron-10 enriched 5 in killing C-6 rat glioma cells by incubating the cells with the compound and subsequent treatment with thermal neutrons. 3 was also administrated iv, in concentrations of 25 mg boron/kg body weight to rats bearing brain tumors. After a period of 4 h after administration the concentration of boron in the tumor tissue was 3.0 ppm. (C) 2001 Elsevier Science Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S0968-0896(01)00061-X"],["dc.identifier.isi","000169580500013"],["dc.identifier.pmid","11425576"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22525"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0968-0896"],["dc.title","ortho-Carboranyl glycosides for the treatment of cancer by boron neutron capture therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","28"],["dc.bibliographiccitation.journal","ChemInform"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Tietze, Lutz F."],["dc.contributor.author","Griesbach, Ulrich"],["dc.contributor.author","Schuberth, Ingrid"],["dc.contributor.author","Bothe, Ulrich"],["dc.contributor.author","Marra, Alberto"],["dc.contributor.author","Dondoni, Alessandro"],["dc.date.accessioned","2021-12-08T12:29:07Z"],["dc.date.available","2021-12-08T12:29:07Z"],["dc.date.issued","2003"],["dc.identifier.doi","10.1002/chin.200328212"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/95961"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-476"],["dc.relation.eissn","1522-2667"],["dc.relation.issn","0931-7597"],["dc.rights.uri","http://doi.wiley.com/10.1002/tdm_license_1.1"],["dc.title","Novel Carboranyl C-Glycosides for the Treatment of Cancer by Boron Neutron Capture Therapy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","no"],["dc.bibliographiccitation.issue","20"],["dc.bibliographiccitation.journal","ChemInform"],["dc.bibliographiccitation.lastpage","no"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Tietze, Lutz F."],["dc.contributor.author","Griesbach, Ulrich"],["dc.contributor.author","Bothe, Ulrich"],["dc.contributor.author","Nakamura, Hiroyuki"],["dc.contributor.author","Yamamoto, Yoshinori"],["dc.date.accessioned","2021-12-08T12:28:58Z"],["dc.date.available","2021-12-08T12:28:58Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1002/chin.200220141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/95911"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-476"],["dc.relation.eissn","1522-2667"],["dc.relation.issn","0931-7597"],["dc.rights.uri","http://doi.wiley.com/10.1002/tdm_license_1.1"],["dc.title","ChemInform Abstract: Novel Carboranes with a DNA Binding Unit for the Treatment of Cancer by Boron Neutron Capture Therapy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","326"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","ChemBioChem"],["dc.bibliographiccitation.lastpage","334"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Tietze, Lutz Friedjan"],["dc.contributor.author","Bothe, U."],["dc.contributor.author","Griesbach, U."],["dc.contributor.author","Nakaichi, M."],["dc.contributor.author","Hasegawa, T."],["dc.contributor.author","Nakamura, H."],["dc.contributor.author","Yamamoto, Y."],["dc.date.accessioned","2018-11-07T09:04:25Z"],["dc.date.available","2018-11-07T09:04:25Z"],["dc.date.issued","2001"],["dc.description.abstract","Boron neutron capture therapy is a special type of radiotherapy for the treatment of cancer by using boron compounds. Problems often arise from the: low water solubility of these compounds, their unselective uptake into the cancer cells, and their toxicity Here we describe the novel water-soluble ortho-carboranyl bisglycosides 7 and 10 containing either lactose or glucose and the mixed bisglycosides 1 and 28 containing glucose mannose, and galactose. The carboranyl bisglycosides show almost no toxicity toward bronchial carcinoma cells of line A549 up to a concentration of 0.50 mM As anticipated, these compounds exhibit nearly no uptake into C6 glioma cells; they can therefore be used for a selective delivery into malignant cells:by using conjugates of glycohydrolases and monoclonal antibodies which bind to tumor-associated antigens, since by enzymatic hydrolysis the bisglycosides are transformed into lipophilic compounds."],["dc.identifier.doi","10.1002/1439-7633(20010504)2:5<326::AID-CBIC326>3.3.CO;2-P"],["dc.identifier.isi","000168615400004"],["dc.identifier.pmid","11828461"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25114"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-v C H Verlag Gmbh"],["dc.relation.issn","1439-4227"],["dc.title","Carboranyl bisglycosides for the treatment of cancer by boron neutron capture therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","836"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Chemistry - A European Journal"],["dc.bibliographiccitation.lastpage","842"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Tietze, Lutz F."],["dc.contributor.author","Bothe, Ulrich"],["dc.contributor.author","Schuberth, Ingrid"],["dc.date.accessioned","2018-11-07T08:48:46Z"],["dc.date.available","2018-11-07T08:48:46Z"],["dc.date.issued","2000"],["dc.description.abstract","The synthesis of new ortho-carboranyl lactosides 8, 17, 19 and glucosides 22 and 23 for the use in boron neutron capture therapy is reported. Carboranyl lactosides 17 and 19 as well as the glucosides 22 and 23 contain a fluorine atom to allow a noninvasive determination of these compounds in tumor cells by F-19-NMR spectroscopy. In cloning efficiency tests on human bronchial carcinoma cells the carboranyl lactosides 17 and 19 displayed almost no cytotoxicity. Thus, the considerably cytotoxic carboranyl alcohol 11 is detoxified when linked to a sugar moiety such as in carboranyl glucoside 22."],["dc.identifier.doi","10.1002/(SICI)1521-3765(20000303)6:5<836::AID-CHEM836>3.0.CO;2-8"],["dc.identifier.isi","000085815200010"],["dc.identifier.pmid","10826605"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21302"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0947-6539"],["dc.title","Preparation of a new carboranyl lactoside for the treatment of cancer by boron neutron capture therapy: Synthesis and toxicity of fluoro carboranyl glycosides for in vivo F-19-NMR spectroscopy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","219"],["dc.bibliographiccitation.issue","2-3"],["dc.bibliographiccitation.journal","ChemBioChem"],["dc.bibliographiccitation.lastpage","225"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Tietze, Lutz Friedjan"],["dc.contributor.author","Griesbach, U."],["dc.contributor.author","Bothe, U."],["dc.contributor.author","Nakamura, H."],["dc.contributor.author","Yamamoto, Y."],["dc.date.accessioned","2018-11-07T10:31:17Z"],["dc.date.available","2018-11-07T10:31:17Z"],["dc.date.issued","2002"],["dc.description.abstract","The synthesis and biological evaluation of two ortho-carborane derivatives which contain a 5,6,7-trimethoxyindole (TMI) unit for use in boron neutron capture therapy is described. The TMI moiety is known to be the DNA-binding part of the highly potent anticancer agent duocarmycin A. The ortho-carborane derivatives were prepared from amino alkynes which were bound to a protected TMI carboxylic acid. Addition of decaborane(14) to the alkyne triple bond with subsequent removal of the tert-butoxy-carbonyl (Boc) and benzyl protecting groups gave the desired product. Boron uptake from the ortho-carborane derivatives into B-16 melanoma cells was higher and faster than that observed with L-p-boronophenylalanine (BPA), which is in use in the clinic."],["dc.identifier.doi","10.1002/1439-7633(20020301)3:2/3<219::AID-CBIC219>3.0.CO;2-#"],["dc.identifier.isi","000174383700012"],["dc.identifier.pmid","11921401"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44071"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-v C H Verlag Gmbh"],["dc.relation.issn","1439-7633"],["dc.relation.issn","1439-4227"],["dc.title","Novel carboranes with a DNA binding unit for the treatment of cancer by boron neutron capture therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]